Table 2. New dosage forms and indications approved by the FDA: August 16, 2014 through September 15, 2014.

Generic name	Brand name (Company)	Indication and comments
New dosage forms/strength/route of administration
Abacavir, dolutegravir, and lamivudine	Triumeq (ViiV HealthCare)	Treatment of HIV-1 infection with a once-daily, single-tablet regimen that contains 600 mg of abacavir (nucleoside analogue reverse transcriptase inhibitor), 50 mg of dolutegravir (integrase strand transfer inhibitor), and 300 mg of lamivudine (nucleoside analogue reverse transcriptase inhibitor)
New indications
Apixaban	Eliquis (Bristol-Myers Squibb)	Treatment of deep vein thrombosis and pulmonary emboli and reduction of risk of recurrent deep vein thrombosis and pulmonary emboli following initial therapy
Diclofenac	Zorvolex (Iroko Pharmaceuticals)	Management of osteoarthritis pain
Eltrombopag	Promacta (GlaxoSmithKline)	Treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy
Enalapril maleate powder for oral solution	Epaned (Silvergate Pharmaceuticals)	Previously approved only for the treatment of hypertension; indication expanded to include treatment of symptomatic heart failure and treatment of asymptomatic left ventricular dysfunction
Enzalutamide	Xtandi (Medivation/Astellas Pharma)	Advanced prostate cancer in men who have not yet received chemotherapy
Lacosamide	Vimpat (UCB)	Monotherapy for the treatment of partial-onset seizures in patients with epilepsy ages 17 years and older